Monitoring potential adverse event rate differences using data from blinded trials: the canary in the coal mine
- 25 September 2016
- journal article
- research article
- Published by Wiley in Statistics in Medicine
- Vol. 36 (1) , 92-104
Abstract
The development of drugs and biologicals whose mechanisms of action may extend beyond their target indications has led to a need to identify unexpected potential toxicities promptly even while blinded clinical trials are under way. One component of recently issued FDA rules regarding safety reporting requirements raises the possibility of breaking the blind for pre‐identified serious adverse events that are not the clinical endpoints of a blinded study. Concern has been expressed that unblinding individual cases of frequently occurring adverse events could compromise the overall validity of the study. However, if external information is available about adverse event rates among patients not receiving the test product in populations similar to the study population, then it may be possible to address the potential for elevated risk without unblinding the trial. This article describes a Bayesian approach for determining the likelihood of elevated risk suitable binomial or Poisson likelihoods that applies regardless of the metric used to express the difference. The method appears to be particularly appropriate for routine monitoring of safety information for project development programs that include large blinded trials. Copyright © 2016 John Wiley & Sons, Ltd.Keywords
This publication has 25 references indexed in Scilit:
- Safety Monitoring in Clinical TrialsPharmaceutics, 2013
- Bayesian heavy-tailed models and conflict resolution: A reviewBrazilian Journal of Probability and Statistics, 2012
- Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear ModelsBayesian Analysis, 2012
- Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical TrialsBiometrics, 2011
- A case for robust Bayesian priors with applications to clinical trialsBayesian Analysis, 2009
- Independent Contribution of Diabetes to Increased Prevalence and Incidence of Atrial FibrillationDiabetes Care, 2009
- A note on the power priorStatistics in Medicine, 2009
- Blinded assessment of treatment effects utilizing information about the randomization block lengthStatistics in Medicine, 2009
- The relationship between the power prior and hierarchical modelsBayesian Analysis, 2006
- Monitoring the Safety of VaccinesDrug Safety, 2002